{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:52:47Z","timestamp":1781646767729,"version":"3.54.5"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Myeloid epithelial reproductive tyrosine kinase (MERTK) receptor is overexpressed in cancers and is associated with poor prognosis. RGX-019-MMAE, a novel humanized IgG1-MMAE antibody-drug conjugate (ADC) (Inspirna, Inc), selectively binds to MERTK with high affinity, resulting in internalization and degradation of the receptor. It then induces cytotoxicity through the release of the payload, MMAE (monomethyl auristatin E), which disrupts mitosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>MERTK protein expression was analyzed in 818 AML patients using Reverse Phase Protein Arrays (RPPA). Expression was also assessed by flow cytometry in eight AML cell lines and peripheral blood or bone marrow mononuclear cells from five AML patients. Cell lines with the highest MERTK expression were treated with varying doses of RGX-019-MMAE or naked antibody for 120\u00a0h, and viability was measured using CellTiter-Glo 2.0. Similarly, primary cells from five AML patients were treated to assess the anti-leukemic effect of RGX-019-MMAE. Further, the combinatorial effects of RGX-019-MMAE with venetoclax (BCL2 inhibitor) were evaluated in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Reverse-phase protein array in 818 primary AML samples revealed significantly high MERTK protein expression in monocytic acute myeloid leukemia (AML), especially in those with PTPN11, RAS, CEBPA mutations, t (9;11) translocation, and high WBC count, suggesting its potential as a therapeutic target in AML. We also observed varying degrees of MERTK expression in AML cell lines, with highest expression in Kasumi-1 and OCI-AML3. Treatment of these cell lines with the anti-MERTK antibody-drug conjugate RGX-019-MMAE resulted in significantly more leukemic cell killing than the control antibody in a dose-dependent manner. We validated this finding in MERTK-expressing primary AML samples expressing MERTK. Interestingly, RGX-019-MMAE had no effect on normal hematopoietic stem cells\u2019 clonogenic potential. Further, treatment with RGX-019-MMAE inhibited AML progression in vivo and significantly prolonged survival of AML xenograft-bearing mice in a dose-dependent manner. Moreover, treatment with RGX-019-MMAE sensitized AML cells to venetoclax in a dose-dependent manner.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MERTK is overexpressed in AML and could serve as a therapeutic target. Furthermore, RGX-019 MMAE can be used as a novel therapeutic approach for treating AML, especially in treating monocytic subsets of AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-026-03657-y","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T01:35:06Z","timestamp":1774661706000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["RGX-019-MMAE inhibits leukemia progression by targeting MER proto-oncogene tyrosine kinase (MERTK) in acute myeloid leukemia"],"prefix":"10.1186","volume":"45","author":[{"given":"Anudishi","family":"Tyagi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Eckstrom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shugaku","family":"Takeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein A.","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Anand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Borgman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kornblau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V. Lokesh","family":"Battula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"4","key":"3657_CR1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/sj.leu.2402446","volume":"16","author":"CT Jordan","year":"2002","unstructured":"Jordan CT. Unique molecular and cellular features of acute myelogenous leukemia stem cells. Leukemia. 2002;16(4):559\u201362.","journal-title":"Leukemia"},{"key":"3657_CR2","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.blre.2019.04.005","volume":"36","author":"RM Shallis","year":"2019","unstructured":"Shallis RM, et al. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70\u201387.","journal-title":"Blood Rev"},{"issue":"1","key":"3657_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s10585-022-10189-0","volume":"40","author":"R Mecklenbrauck","year":"2023","unstructured":"Mecklenbrauck R, Heuser M. Resistance to targeted therapies in acute myeloid leukemia. Clin Exp Metastasis. 2023;40(1):33\u201344.","journal-title":"Clin Exp Metastasis"},{"issue":"6","key":"3657_CR4","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas A, Teicher BA, Hassan R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 2016;17(6):e254\u201362.","journal-title":"Lancet Oncol"},{"issue":"1","key":"3657_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, et al. Antibody drug conjugate: the biological missile for targeted cancer therapy. Signal Transduct Target Ther. 2022;7(1):93.","journal-title":"Signal Transduct Target Ther"},{"key":"3657_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.drup.2014.11.001","volume":"18","author":"L Shefet-Carasso","year":"2015","unstructured":"Shefet-Carasso L, Benhar I. Antibody-targeted drugs and drug resistance\u2013challenges and solutions. Drug Resist Updat. 2015;18:36\u201346.","journal-title":"Drug Resist Updat"},{"issue":"1","key":"3657_CR7","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12943-024-01963-7","volume":"23","author":"K Liu","year":"2024","unstructured":"Liu K, et al. A review of the clinical efficacy of FDA-approved antibody\u2013drug conjugates in human cancers. Mol Cancer. 2024;23(1):62.","journal-title":"Mol Cancer"},{"key":"3657_CR8","doi-asserted-by":"publisher","first-page":"1203073","DOI":"10.3389\/fimmu.2023.1203073","volume":"14","author":"D Aggarwal","year":"2023","unstructured":"Aggarwal D, et al. Antibody-drug conjugates: the paradigm shifts in the targeted cancer therapy. Front Immunol. 2023;14:1203073.","journal-title":"Front Immunol"},{"issue":"49","key":"3657_CR9","doi-asserted-by":"publisher","first-page":"5548","DOI":"10.1038\/sj.onc.1203957","volume":"19","author":"DR Robinson","year":"2000","unstructured":"Robinson DR, Wu YM, Lin SF. The protein tyrosine kinase family of the human genome. Oncogene. 2000;19(49):5548\u201357.","journal-title":"Oncogene"},{"key":"3657_CR10","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","volume":"100","author":"RM Linger","year":"2008","unstructured":"Linger RM, et al. TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res. 2008;100:35\u201383.","journal-title":"Adv Cancer Res"},{"key":"3657_CR11","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/bs.ircmb.2022.04.004","volume":"368","author":"KC Lahey","year":"2022","unstructured":"Lahey KC, et al. Mertk: an emerging target in cancer biology and immuno-oncology. Int Rev Cell Mol Biol. 2022;368:35\u201359.","journal-title":"Int Rev Cell Mol Biol"},{"issue":"46","key":"3657_CR12","doi-asserted-by":"publisher","first-page":"5359","DOI":"10.1038\/onc.2013.40","volume":"32","author":"AB Lee-Sherick","year":"2013","unstructured":"Lee-Sherick AB, et al. Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia. Oncogene. 2013;32(46):5359\u201368.","journal-title":"Oncogene"},{"issue":"9","key":"3657_CR13","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2013-01-478156","volume":"122","author":"RM Linger","year":"2013","unstructured":"Linger RM, et al. Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood. 2013;122(9):1599\u2013609.","journal-title":"Blood"},{"issue":"3","key":"3657_CR14","doi-asserted-by":"publisher","first-page":"e85630","DOI":"10.1172\/jci.insight.85630","volume":"1","author":"KA Minson","year":"2016","unstructured":"Minson KA, et al. The MERTK\/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight. 2016;1(3):e85630.","journal-title":"JCI Insight"},{"issue":"11","key":"3657_CR15","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1158\/1535-7163.MCT-17-1239","volume":"17","author":"NK McDaniel","year":"2018","unstructured":"McDaniel NK, et al. MERTK mediates intrinsic and adaptive resistance to AXL-targeting agents. Mol Cancer Ther. 2018;17(11):2297\u2013308.","journal-title":"Mol Cancer Ther"},{"issue":"24","key":"3657_CR16","doi-asserted-by":"publisher","first-page":"6523","DOI":"10.1158\/1078-0432.CCR-18-0040","volume":"24","author":"D Yan","year":"2018","unstructured":"Yan D, et al. MERTK promotes resistance to irreversible EGFR tyrosine kinase inhibitors in Non-small cell lung cancers expressing Wild-type EGFR family members. Clin Cancer Res. 2018;24(24):6523\u201335.","journal-title":"Clin Cancer Res"},{"key":"3657_CR17","doi-asserted-by":"crossref","unstructured":"Chen CJ, Liu YP. MERTK inhibition: potential as a treatment strategy in EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancer. Pharmaceuticals (Basel). 2021;14(2):130.","DOI":"10.3390\/ph14020130"},{"key":"3657_CR18","doi-asserted-by":"publisher","first-page":"107577","DOI":"10.1016\/j.pharmthera.2020.107577","volume":"213","author":"JM Huelse","year":"2020","unstructured":"Huelse JM, et al. MERTK in cancer therapy: targeting the receptor tyrosine kinase in tumor cells and the immune system. Pharmacol Ther. 2020;213:107577.","journal-title":"Pharmacol Ther"},{"issue":"2","key":"3657_CR19","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.exphem.2009.11.002","volume":"38","author":"Y Shiozawa","year":"2010","unstructured":"Shiozawa Y, Pedersen EA, Taichman RS. GAS6\/Mer axis regulates the homing and survival of the E2A\/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche. Exp Hematol. 2010;38(2):132\u201340.","journal-title":"Exp Hematol"},{"issue":"1","key":"3657_CR20","doi-asserted-by":"publisher","first-page":"e101","DOI":"10.1038\/bcj.2012.46","volume":"3","author":"LN Brandao","year":"2013","unstructured":"Brandao LN, et al. Inhibition of MerTK increases chemosensitivity and decreases oncogenic potential in T-cell acute lymphoblastic leukemia. Blood Cancer J. 2013;3(1):e101.","journal-title":"Blood Cancer J"},{"issue":"2","key":"3657_CR21","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.immuni.2020.01.014","volume":"52","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, et al. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP. Immunity. 2020;52(2):357\u2013e3739.","journal-title":"Immunity"},{"issue":"7","key":"3657_CR22","doi-asserted-by":"publisher","first-page":"2358","DOI":"10.1182\/blood-2006-02-003475","volume":"108","author":"SM Kornblau","year":"2006","unstructured":"Kornblau SM, et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood. 2006;108(7):2358\u201365.","journal-title":"Blood"},{"key":"3657_CR23","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/978-1-61779-286-1_10","volume":"785","author":"SM Kornblau","year":"2011","unstructured":"Kornblau SM, Coombes KR. Use of reverse phase protein microarrays to study protein expression in leukemia: technical and methodological lessons learned. Methods Mol Biol. 2011;785:141\u201355.","journal-title":"Methods Mol Biol"},{"issue":"5","key":"3657_CR24","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41375-024-02208-8","volume":"38","author":"ES de Camargo Magalh\u00e3es","year":"2024","unstructured":"de Camargo Magalh\u00e3es ES, et al. Proteomics for optimizing therapy in acute myeloid leukemia: venetoclax plus hypomethylating agents versus conventional chemotherapy. Leukemia. 2024;38(5):1046\u201356.","journal-title":"Leukemia"},{"issue":"10","key":"3657_CR25","doi-asserted-by":"publisher","first-page":"2512","DOI":"10.1158\/1535-7163.MCT-06-0334","volume":"5","author":"R Tibes","year":"2006","unstructured":"Tibes R, et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther. 2006;5(10):2512\u201321.","journal-title":"Mol Cancer Ther"},{"issue":"18","key":"3657_CR26","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1182\/blood.2021014671","volume":"139","author":"A Tyagi","year":"2022","unstructured":"Tyagi A, et al. Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML. Blood. 2022;139(18):2782\u201396.","journal-title":"Blood"},{"issue":"1","key":"3657_CR27","doi-asserted-by":"publisher","first-page":"2801","DOI":"10.1038\/s41467-022-30396-3","volume":"13","author":"N Baran","year":"2022","unstructured":"Baran N, et al. Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia. Nat Commun. 2022;13(1):2801.","journal-title":"Nat Commun"},{"issue":"12","key":"3657_CR28","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2006-04-017061","volume":"108","author":"J Vera","year":"2006","unstructured":"Vera J, et al. T lymphocytes redirected against the kappa light chain of human Immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006;108(12):3890\u20137.","journal-title":"Blood"},{"issue":"16suppl","key":"3657_CR29","doi-asserted-by":"publisher","first-page":"e15103","DOI":"10.1200\/JCO.2023.41.16_suppl.e15103","volume":"41","author":"S Takeda","year":"2023","unstructured":"Takeda S, et al. A MERTK-Targeting Antibody-Drug Conjugate Selectively Depletes M2 Tumor-Associated Macrophages and MERTK-Expressing Cancer Cells. Cancer Research. 2026. https:\/\/pubmed.ncbi.nlm.nih.gov\/41661650\/.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3657_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424\u201347.","journal-title":"Blood"},{"issue":"9","key":"3657_CR31","doi-asserted-by":"publisher","first-page":"6722","DOI":"10.18632\/oncotarget.3156","volume":"6","author":"AB Lee-Sherick","year":"2015","unstructured":"Lee-Sherick AB, et al. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget. 2015;6(9):6722\u201336.","journal-title":"Oncotarget"},{"issue":"7","key":"3657_CR32","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.4049\/jimmunol.1200662","volume":"189","author":"G Zizzo","year":"2012","unstructured":"Zizzo G, et al. Efficient clearance of early apoptotic cells by human macrophages requires M2c polarization and MerTK induction. J Immunol. 2012;189(7):3508\u201320.","journal-title":"J Immunol"},{"key":"3657_CR33","doi-asserted-by":"crossref","unstructured":"Huey MG et al. Targeting the TAM receptors in leukemia. Cancers (Basel). 2016;8(11):101.","DOI":"10.3390\/cancers8110101"},{"key":"3657_CR34","doi-asserted-by":"publisher","first-page":"107547","DOI":"10.1016\/j.leukres.2024.107547","volume":"144","author":"S Wu","year":"2024","unstructured":"Wu S, et al. Combining the novel FLT3 and MERTK dual inhibitor MRX-2843 with venetoclax results in promising antileukemic activity against FLT3-ITD AML. Leuk Res. 2024;144:107547.","journal-title":"Leuk Res"},{"issue":"6","key":"3657_CR35","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.3324\/haematol.2021.278369","volume":"107","author":"SM Post","year":"2022","unstructured":"Post SM, et al. AXL\/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3-ITD acute myeloid leukemia. Haematologica. 2022;107(6):1311\u201322.","journal-title":"Haematologica"},{"issue":"9","key":"3657_CR36","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/sj.leu.2401130","volume":"12","author":"H Kiyoi","year":"1998","unstructured":"Kiyoi H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12(9):1333\u20137.","journal-title":"Leukemia"},{"issue":"5","key":"3657_CR37","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1038\/sj.onc.1203354","volume":"19","author":"F Hayakawa","year":"2000","unstructured":"Hayakawa F, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19(5):624\u201331.","journal-title":"Oncogene"},{"issue":"12","key":"3657_CR38","doi-asserted-by":"publisher","first-page":"2382","DOI":"10.1038\/leu.2015.147","volume":"29","author":"IK Park","year":"2015","unstructured":"Park IK, et al. Receptor tyrosine kinase Axl is required for resistance of leukemic cells to FLT3-targeted therapy in acute myeloid leukemia. Leukemia. 2015;29(12):2382\u20139.","journal-title":"Leukemia"},{"issue":"6","key":"3657_CR39","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/leu.2013.371","volume":"28","author":"SP Whitman","year":"2014","unstructured":"Whitman SP, et al. GAS6 expression identifies high-risk adult AML patients: potential implications for therapy. Leukemia. 2014;28(6):1252\u20138.","journal-title":"Leukemia"},{"issue":"9","key":"3657_CR40","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1182\/blood.2021015246","volume":"141","author":"M Roas","year":"2023","unstructured":"Roas M, et al. Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML. Blood. 2023;141(9):1023\u201335.","journal-title":"Blood"},{"key":"3657_CR41","doi-asserted-by":"crossref","unstructured":"Joubert N et al. Antibody-drug conjugates: the last decade. Pharmaceuticals (Basel). 2020;13(9):245.","DOI":"10.3390\/ph13090245"},{"key":"3657_CR42","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jconrel.2018.07.024","volume":"286","author":"J Guo","year":"2018","unstructured":"Guo J, et al. The potential for clinical translation of antibody-targeted nanoparticles in the treatment of acute myeloid leukaemia. J Control Release. 2018;286:154\u201366.","journal-title":"J Control Release"},{"issue":"9","key":"3657_CR43","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1158\/1078-0432.CCR-05-2208","volume":"12","author":"DK Graham","year":"2006","unstructured":"Graham DK, et al. Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res. 2006;12(9):2662\u20139.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3657_CR44","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.immuni.2018.01.007","volume":"48","author":"BV Kumar","year":"2018","unstructured":"Kumar BV, Connors TJ, Farber DL. Human T cell Development, Localization, and function throughout life. Immunity. 2018;48(2):202\u201313.","journal-title":"Immunity"},{"issue":"14","key":"3657_CR45","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","volume":"2","author":"YP Jiang","year":"2018","unstructured":"Jiang YP, et al. CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv. 2018;2(14):1738\u201349.","journal-title":"Blood Adv"},{"issue":"8","key":"3657_CR46","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1182\/blood-2013-03-491506","volume":"122","author":"MS Kung Sutherland","year":"2013","unstructured":"Kung Sutherland MS, et al. SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML. Blood. 2013;122(8):1455\u201363.","journal-title":"Blood"},{"issue":"1","key":"3657_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1038\/sj.leu.2402740","volume":"17","author":"H Quentmeier","year":"2003","unstructured":"Quentmeier H, et al. FLT3 mutations in acute myeloid leukemia cell lines. Leukemia. 2003;17(1):120\u20134.","journal-title":"Leukemia"},{"issue":"2","key":"3657_CR48","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ccr.2011.06.029","volume":"20","author":"Y Kikushige","year":"2011","unstructured":"Kikushige Y, et al. Self-renewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011;20(2):246\u201359.","journal-title":"Cancer Cell"},{"issue":"3","key":"3657_CR49","first-page":"706","volume":"110","author":"V Zelikson","year":"2025","unstructured":"Zelikson V, et al. Loncastuximab in high-risk and heavily pretreated relapsed\/refractory diffuse large B-cell lymphoma: a Realworld analysis from 21 US centers. Haematologica. 2025;110(3):706\u201314.","journal-title":"Haematologica"},{"issue":"5","key":"3657_CR50","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s002800050989","volume":"44","author":"LG Wang","year":"1999","unstructured":"Wang LG, et al. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol. 1999;44(5):355\u201361.","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-026-03657-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-026-03657-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:01:36Z","timestamp":1781643696000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13046-026-03657-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3657"],"URL":"https:\/\/doi.org\/10.1186\/s13046-026-03657-y","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: Graphical Abstract was missing in the published article","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The sample collection was conducted according to a protocol approved by the Institutional Review Board at The University of Texas MD Anderson Cancer Center (Protocol PA18-0129), and all study participants provided written informed consent. All mouse experiments were performed in accordance with MD Anderson Institutional Animal Care and Use Committee guidelines and were approved by the committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This work was supported by Inspirna, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}